<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cnr270171" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Rep (Hoboken)</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Rep (Hoboken)</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2573-8348</journal-id><journal-id journal-id-type="publisher-id">CNR2</journal-id><journal-title-group><journal-title>Cancer Reports</journal-title></journal-title-group><issn pub-type="epub">2573-8348</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40176408</article-id><article-id pub-id-type="pmc">PMC11965703</article-id>
<article-id pub-id-type="doi">10.1002/cnr2.70171</article-id><article-id pub-id-type="publisher-id">CNR270171</article-id><article-id pub-id-type="other">CNR2-24-1091.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant&#x02010;Eligible Multiple Myeloma: A Systematic Review and Meta&#x02010;Analysis</article-title></title-group><contrib-group><contrib id="cnr270171-cr-0001" contrib-type="author" corresp="yes"><name><surname>Channar</surname><given-names>Aneeta</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-2698-0946</contrib-id><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>aneetachannar96@gmail.com</email></address></contrib><contrib id="cnr270171-cr-0002" contrib-type="author"><name><surname>Naqvi</surname><given-names>Syed Arsalan Ahmed</given-names></name><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cnr270171-cr-0003" contrib-type="author"><name><surname>Khan</surname><given-names>Muhammad Ali</given-names></name><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cnr270171-cr-0004" contrib-type="author"><name><surname>Bibi</surname><given-names>Arifa</given-names></name><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cnr270171-cr-0005" contrib-type="author"><name><surname>Saxena</surname><given-names>Akshat</given-names></name><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cnr270171-cr-0006" contrib-type="author"><name><surname>Tripathi</surname><given-names>Nikita</given-names></name><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cnr270171-cr-0007" contrib-type="author"><name><surname>Iftikhar</surname><given-names>Ahmad</given-names></name><xref rid="cnr270171-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cnr270171-cr-0008" contrib-type="author"><name><surname>Raina</surname><given-names>Ammad</given-names></name><xref rid="cnr270171-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cnr270171-cr-0009" contrib-type="author"><name><surname>Khakwani</surname><given-names>Kaneez Zahra Rubab</given-names></name><xref rid="cnr270171-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cnr270171-cr-0010" contrib-type="author"><name><surname>Riaz</surname><given-names>Irbaz Bin</given-names></name><xref rid="cnr270171-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cnr270171-cr-0011" contrib-type="author"><name><surname>Husnain</surname><given-names>Muhammad</given-names></name><xref rid="cnr270171-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cnr270171-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Division of Hematology and Medical Oncology</named-content>
<institution>Mayo Clinic</institution>
<city>Phoenix</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><aff id="cnr270171-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>The University of Arizona</institution>
<city>Tucson</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><aff id="cnr270171-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Canyon Vista Medical Center</institution>
<city>Sierra Vista</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Aneeta Channar (<email>aneetachannar96@gmail.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>8</volume><issue seq="68">4</issue><issue-id pub-id-type="doi">10.1002/cnr2.v8.4</issue-id><elocation-id>e70171</elocation-id><history>
<date date-type="rev-recd"><day>17</day><month>2</month><year>2025</year></date>
<date date-type="received"><day>09</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>20</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Wiley Periodicals LLC.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Cancer Reports</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CNR2-8-e70171.pdf"/><abstract><title>ABSTRACT</title><sec id="cnr270171-sec-0001"><title>Background</title><p>The treatment landscape for multiple myeloma continues to evolve. Recently, the addition of anti&#x02010;CD38 monoclonal antibodies (mAbs) to the triplet regimen, comprising a proteasome inhibitor, an immunomodulatory agent, and a steroid, for transplant&#x02010;eligible newly diagnosed multiple myeloma (TENDMM) has shown promising results.</p></sec><sec id="cnr270171-sec-0002"><title>Aims</title><p>To evaluate the overall efficacy and safety of quadruplet therapy with an anti&#x02010;CD38 mAb compared to a triplet regimen.</p></sec><sec id="cnr270171-sec-0003"><title>Methods</title><p>A systematic search of Medline, Scopus, and EMBASE databases from inception to July 2024 identified relevant randomized controlled trials (RCTs). Efficacy and safety outcomes were derived using random&#x02010;effects meta&#x02010;analysis. Summarized outcomes include hazard ratios (HR) for progression&#x02010;free survival (PFS) and overall survival (OS), odds ratios (OR) for response rates, measurable residual disease (MRD) negativity rate, and grade 3 or higher adverse events (G&#x02009;&#x02265;&#x02009;3 AEs).</p></sec><sec id="cnr270171-sec-0004"><title>Results</title><p>Five RCTs involving 2963 patients were included. A statistically significant PFS was observed for quadruplet therapy when compared to the triplet regimen (HR 0.44; 95% Confidence Interval [CI] 0.35&#x02013;0.56). PFS benefit was consistent for the standard risk (SR) group (HR 0.38; 95% CI 0.27&#x02013;0.52) and high risk (HiR) group (HR 0.62; 95% CI 0.41&#x02013;0.92). No statistically significant benefit was observed for OS (HR 0.55; 95% CI 0.28&#x02013;1.08). A statistically significant benefit was observed for the overall response rate (OR 1.77; 95% CI 1.02&#x02013;3.06) and MRD negativity rate (OR 2.67; 95% CI 1.79&#x02013;3.99). No significant differences were observed for G&#x02009;&#x02265;&#x02009;3 AE (OR 1.21; 95% CI 0.92&#x02013;1.58), lymphopenia (OR 1.09; 95% CI 0.62&#x02013;1.89), and anemia (OR 1.06; 95% CI 0.83&#x02013;1.37). However, a significantly increased risk was observed for all&#x02010;grade thrombocytopenia (OR 1.64; 95% CI 1.37&#x02013;1.97), neutropenia (OR 2.24; 95% CI 1.67&#x02013;3.02) and infections (OR 1.88; 95% CI 1.07&#x02013;3.31).</p></sec><sec id="cnr270171-sec-0005"><title>Conclusion</title><p>Quadruplet therapy demonstrated a favorable efficacy and safety profile, with consistent benefit across subgroups. The findings support its potential as the new standard of care for TENDMM.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cnr270171-kwd-0001">anti&#x02010;CD38 antibody</kwd><kwd id="cnr270171-kwd-0002">daratumumab</kwd><kwd id="cnr270171-kwd-0003">isatuximab</kwd><kwd id="cnr270171-kwd-0004">multiple myeloma</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="8"/><word-count count="4700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:07.04.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cnr270171-ntgp-0001"><fn fn-type="funding" id="cnr270171-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="cnr270171-body-0001"><sec id="cnr270171-sec-0006"><label>1</label><title>Introduction</title><p>Multiple myeloma (MM) is the second most common hematological cancer [<xref rid="cnr270171-bib-0001" ref-type="bibr">1</xref>], with approximately 32&#x02009;000 new cases diagnosed each year in the United States [<xref rid="cnr270171-bib-0002" ref-type="bibr">2</xref>]. Although the survival for MM patients has improved significantly over the past decade, reaching a median of 8&#x02013;10&#x02009;years [<xref rid="cnr270171-bib-0003" ref-type="bibr">3</xref>], the disease remains incurable, underscoring the need for novel therapeutic approaches to further enhance patient outcomes [<xref rid="cnr270171-bib-0004" ref-type="bibr">4</xref>]. Risk stratification and eligibility for autologous stem cell transplantation (ASCT) pose important caveats to the treatment of newly diagnosed multiple myeloma [<xref rid="cnr270171-bib-0005" ref-type="bibr">5</xref>]. Historically, the triplet therapy consisting of a proteasome inhibitor, an immunomodulatory agent, and a steroid had long been the standard of care for transplant&#x02010;eligible newly diagnosed multiple myeloma (TENDMM) [<xref rid="cnr270171-bib-0006" ref-type="bibr">6</xref>]. However, in recent years, the therapeutic landscape of MM has evolved with the introduction of multiple monoclonal antibodies (mAbs). Notably, anti&#x02010;CD38 mAbs, Daratumumab (Dara) and Isatuximab (Isa) have demonstrated substantial efficacy, which has led to their initial FDA approval for relapsed/refractory multiple myeloma (RRMM) [<xref rid="cnr270171-bib-0007" ref-type="bibr">7</xref>].</p><p>CASSIOPEIA [<xref rid="cnr270171-bib-0008" ref-type="bibr">8</xref>] was the first phase three randomized controlled trial (RCT) to provide evidence for the efficacy of Dara&#x02010;based induction and consolidation in TENDMM. Subsequently, trials such as GRIFFIN [<xref rid="cnr270171-bib-0009" ref-type="bibr">9</xref>] and PERSEUS [<xref rid="cnr270171-bib-0010" ref-type="bibr">10</xref>] have provided further evidence that Dara&#x02010;based regimen yields prolonged and deeper responses in TENDMM. The earliest evidence for the incorporation of Isa comes from the GMMG&#x02010;HD 7 trial [<xref rid="cnr270171-bib-0011" ref-type="bibr">11</xref>], followed by the Iskia trial [<xref rid="cnr270171-bib-0012" ref-type="bibr">12</xref>], both of which reported that the Isa&#x02010;based arms yielded superior responses. Sustained deep responses to initial therapy are in turn associated with improved survival outcomes, particularly an increase in progression&#x02010;free survival (PFS) [<xref rid="cnr270171-bib-0013" ref-type="bibr">13</xref>]. Previous meta&#x02010;analyses, conducted since 2019, have evaluated Dara&#x02010;based quadruplets in frontline MM [<xref rid="cnr270171-bib-0014" ref-type="bibr">14</xref>, <xref rid="cnr270171-bib-0015" ref-type="bibr">15</xref>, <xref rid="cnr270171-bib-0016" ref-type="bibr">16</xref>, <xref rid="cnr270171-bib-0017" ref-type="bibr">17</xref>]. However, with rapidly evolving evidence, this systematic review and meta&#x02010;analysis aims to provide a comprehensive summary of the overall efficacy and safety of quadruplet therapy with anti&#x02010;CD38 (Dara or Isa) in TENDMM, incorporating the latest reports from clinical trials. Our analysis focuses on the transplant&#x02010;eligible cohort to guide clinicians in selecting the best possible regimen for this group. Additionally, our study provides an in&#x02010;depth evaluation of efficacy across clinically relevant subgroups, offering valuable insights into optimizing treatment strategies for TENDMM patients.</p></sec><sec sec-type="methods" id="cnr270171-sec-0007"><label>2</label><title>Methods</title><p>This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;analysis (PRISMA) guidelines [<xref rid="cnr270171-bib-0018" ref-type="bibr">18</xref>]. A protocol was designed before the research began; however, the review protocol has not been registered.</p><sec id="cnr270171-sec-0008"><label>2.1</label><title>Literature Search and Study Selection</title><p>The search strategy was designed with input from study investigators. Ovid Medline, EMBASE, and SCOPUS were searched from each database's inception (MEDLINE, 1946; EMBASE, 1974; SCOPUS, 2004) through July&#x000a0;1, 2024, to retrieve all phase 2 or phase 3 RCTs comparing quadruplet therapy with anti&#x02010;CD38 monoclonal antibody (Dara or Isa) to the triplet regimen in TENDMM. Studies involving patient populations that had received prior interventions were excluded. In addition, major oncology proceedings (American Society of Clinical Oncology, American Society of Hematology, and European Society for Medical Oncology) were manually searched from 2016 to 2024 for published abstracts. The inclusion criteria were limited to English&#x02010;language articles only. Following de&#x02010;duplication, two reviewers (A.C and S.A.A.N) performed an independent screening of titles and abstracts identified by the search, followed by a detailed full&#x02010;text evaluation for eligibility. Any disagreement between the two reviewers was resolved by input from a third reviewer (M.H). The detailed search strategy is presented in eMethods in the supplement.</p></sec><sec id="cnr270171-sec-0009"><label>2.2</label><title>Data Extraction</title><p>Two independent reviewers (A.C and M.H) extracted the data using standardized data collection forms. Discrepancies were resolved by a third reviewer (I.B.R). Retrieved data included trial characteristics such as publication year, authors, sample size, interventions, duration of follow&#x02010;up, and reported outcomes. Additionally, baseline characteristics of the patient population (age, sex, race/ethnicity, and cytogenetic risk category) were also extracted.</p></sec><sec id="cnr270171-sec-0010"><label>2.3</label><title>Outcomes of Interest</title><p>The efficacy outcomes included PFS, overall survival (OS), measurable residual disease (MRD) negativity rate, overall response rate (ORR), rate of stringent complete response (sCR), very good partial response or better (VGPR or better), and complete response or better (CR or better). Safety outcomes included the risk of grade 3 or higher adverse events (G&#x02009;&#x02265;&#x02009;3), cytopenia, and infections. We extracted the MRD negativity rate with a threshold of 10<sup>&#x02212;5</sup>, as it was consistently reported in the trials. Outcomes were defined in accordance with the definitions provided in the included trials (Table&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S2</xref> in supplement). If multiple publications were available for a trial, data from the publication with the longest follow&#x02010;up were used to derive efficacy outcomes.</p></sec><sec id="cnr270171-sec-0011"><label>2.4</label><title>Risk of Bias</title><p>Risk of bias was assessed for each outcome using the Cochrane Collaboration's tool [<xref rid="cnr270171-bib-0019" ref-type="bibr">19</xref>]. Two reviewers independently evaluated trial quality (A.C and S.A.A.N), with disagreements resolved by referring to a third reviewer (M.H).</p></sec><sec id="cnr270171-sec-0012"><label>2.5</label><title>Statistical Analysis</title><p>A DerSimonian&#x02010;Laird random&#x02010;effects meta&#x02010;analysis was conducted to estimate the summary effect size. For survival outcomes, including PFS and OS, an inverse variance approach was used to pool pre&#x02010;computed hazard ratios (HR) with 95% confidence intervals (CI) after logarithmic transformation. For raw binary outcomes, which included both efficacy and safety outcomes, the Mantel&#x02013;Haenszel approach was used to pool and compute odds ratios with 95% CIs. The Cochrane <italic toggle="yes">Q</italic> test was used to assess statistically significant heterogeneity not explained by chance, and the <italic toggle="yes">I</italic>
<sup>2</sup> statistical test was used to quantify total observed variance due to between&#x02010;study variances. An <italic toggle="yes">I</italic>
<sup>2</sup> statistic greater than 50% indicates substantial heterogeneity. A 2&#x02010;sided <italic toggle="yes">p</italic>&#x02010;value was used, with results considered significant if <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05. Pre&#x02010;specified subgroup analyzes for PFS were performed by cytogenetic risk group. Additional subgroup analyzes were performed for MRD negativity by cytogenetic risk, number of abnormal cytogenetic features (Double&#x02010;hit vs. Single&#x02010;hit), International Staging System (ISS) score, Eastern Cooperative Oncology Group (ECOG) score, and type of MM (IgG vs. non&#x02010;IgG). A <italic toggle="yes">p</italic>&#x02010;value of interaction (<italic toggle="yes">P</italic>
<sub>int</sub>) was computed to detect significant interaction between the subgroups, with a value of &#x0003c;&#x02009;0.10 considered statistically significant. The statistical analyzes were conducted in R (version 4.4.1, R Project for Statistical Computing).</p></sec><sec id="cnr270171-sec-0013"><label>2.6</label><title>Certainty of Evidence</title><p>GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation) was used to evaluate the certainty of evidence. Two reviewers (A.C and S.A.A.N) independently ascertained the certainty in estimates, with disagreement resolved by a third reviewer (M.H).</p></sec></sec><sec sec-type="results" id="cnr270171-sec-0014"><label>3</label><title>Results</title><p>A total of 11&#x02009;762 studies were identified through the search strategy for the databases. An additional conference abstract was identified through a manual search [<xref rid="cnr270171-bib-0012" ref-type="bibr">12</xref>]. After thorough screening, five trials (seven references) [<xref rid="cnr270171-bib-0008" ref-type="bibr">8</xref>, <xref rid="cnr270171-bib-0009" ref-type="bibr">9</xref>, <xref rid="cnr270171-bib-0010" ref-type="bibr">10</xref>, <xref rid="cnr270171-bib-0011" ref-type="bibr">11</xref>, <xref rid="cnr270171-bib-0012" ref-type="bibr">12</xref>, <xref rid="cnr270171-bib-0020" ref-type="bibr">20</xref>, <xref rid="cnr270171-bib-0021" ref-type="bibr">21</xref>] with a total of 2963 patients were included in the systematic review and meta&#x02010;analysis. The process of study selection is outlined in Figure&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S1</xref> in the supplement.</p><sec id="cnr270171-sec-0015"><label>3.1</label><title>Baseline Study and Population Characteristics</title><p>Among the five trials included, three evaluated daratumumab&#x02010;based regimens: two trials investigated Dara in combination with bortezomib, lenalidomide, and dexamethasone (RVd), while one examined daratumumab with bortezomib, thalidomide, and dexamethasone (VTd). The remaining two trials assessed Isa&#x02010;based regimens: one in combination with carfilzomib, lenalidomide, and dexamethasone (KRd), and the other with RVd. Baseline patient characteristics were comparable across studies. From the reported data in the trials, the patient population consisted of 1579 males (56.39%) and 1221 females (43.61%). The trial participants included 1468 individuals reported as White (96.3%), 39 as Black (2.6%), and 13 as Asian (0.9%). High&#x02010;risk cytogenetics (HiR) were reported in 373 patients (17.2%), while 1795 patients (82.7%) were categorized as standard risk (SR). The median age of the patient population was 59.5&#x02009;years (Interquartile range [IQR] 59&#x02013;60.25), and the median follow&#x02010;up time was 21&#x02009;months (IQR 18.8&#x02013;47.5). Additional baseline characteristics are shown in Table&#x000a0;<xref rid="cnr270171-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="cnr270171-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Characteristics of the included trials.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Trial</th><th align="center" valign="bottom" rowspan="1" colspan="1">Phase</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median follow&#x02010;up (months)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Arm</th><th align="center" valign="bottom" rowspan="1" colspan="1">No of patients</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median Age (Range)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Race: <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Male: <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Female: <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">High&#x02010;risk: <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standard&#x02010;risk: <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="2" valign="top" colspan="1">Moreau 2019, (CASSIOPEIA) [<xref rid="cnr270171-bib-0008" ref-type="bibr">8</xref>].</td><td align="center" rowspan="2" valign="top" colspan="1">3</td><td align="center" rowspan="2" valign="top" colspan="1">18.8</td><td align="center" valign="top" rowspan="1" colspan="1">D&#x02010;VTd</td><td align="center" valign="top" rowspan="1" colspan="1">543</td><td align="center" valign="top" rowspan="1" colspan="1">59 (22&#x02013;65)</td><td align="center" rowspan="2" valign="top" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">316 (58.2)</td><td align="center" valign="top" rowspan="1" colspan="1">227 (41.8)</td><td align="center" valign="top" rowspan="1" colspan="1">82 (15)</td><td align="center" valign="top" rowspan="1" colspan="1">460 (85)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VTd</td><td align="center" valign="top" rowspan="1" colspan="1">542</td><td align="center" valign="top" rowspan="1" colspan="1">58 (26&#x02013;65)</td><td align="center" valign="top" rowspan="1" colspan="1">319 (58.9)</td><td align="center" valign="top" rowspan="1" colspan="1">223 (41.1)</td><td align="center" valign="top" rowspan="1" colspan="1">86 (16)</td><td align="center" valign="top" rowspan="1" colspan="1">454 (84)</td></tr><tr><td align="left" rowspan="8" valign="top" colspan="1">Goldschmidt, 2022 (GMMG&#x02010;HD 7) [<xref rid="cnr270171-bib-0011" ref-type="bibr">11</xref>].</td><td align="center" rowspan="8" valign="top" colspan="1">3</td><td align="center" rowspan="8" valign="top" colspan="1">4.1</td><td align="center" rowspan="4" valign="top" colspan="1">Isa&#x02010;RVd</td><td align="center" rowspan="4" valign="top" colspan="1">331</td><td align="center" rowspan="4" valign="top" colspan="1">59 (54&#x02013;64)</td><td align="center" valign="top" rowspan="1" colspan="1">White 327 (99)</td><td align="center" rowspan="4" valign="top" colspan="1">204 (62)</td><td align="center" rowspan="4" valign="top" colspan="1">127 (38)</td><td align="center" rowspan="4" valign="top" colspan="1">58 (18)</td><td align="center" rowspan="4" valign="top" colspan="1">254 (77)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">African 1 (&#x0003c;&#x02009;1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Arabic 1 (&#x0003c;&#x02009;1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Asian 2 (&#x0003c;&#x02009;1)</td></tr><tr><td align="center" rowspan="4" valign="top" colspan="1">RVd</td><td align="center" rowspan="4" valign="top" colspan="1">329</td><td align="center" rowspan="4" valign="top" colspan="1">60 (54&#x02013;65)</td><td align="center" valign="top" rowspan="1" colspan="1">White 327 (99)</td><td align="center" rowspan="4" valign="top" colspan="1">206 (63)</td><td align="center" rowspan="4" valign="top" colspan="1">123 (37)</td><td align="center" rowspan="4" valign="top" colspan="1">66 (20)</td><td align="center" rowspan="4" valign="top" colspan="1">234 (71)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">African 1 (&#x0003c;&#x02009;1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Arabic 0</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Asian 1 (&#x0003c;&#x02009;1)</td></tr><tr><td align="left" rowspan="8" valign="top" colspan="1">Voorhees, 2023 (GRIFFIN) [<xref rid="cnr270171-bib-0009" ref-type="bibr">9</xref>, <xref rid="cnr270171-bib-0020" ref-type="bibr">20</xref>].</td><td align="center" rowspan="8" valign="top" colspan="1">2</td><td align="center" rowspan="8" valign="top" colspan="1">49.6</td><td align="center" rowspan="4" valign="top" colspan="1">D&#x02010;RVd</td><td align="center" rowspan="4" valign="top" colspan="1">104</td><td align="center" rowspan="4" valign="top" colspan="1">59 (51&#x02013;65.5)</td><td align="center" valign="top" rowspan="1" colspan="1">White 85 (82)</td><td align="center" rowspan="4" valign="top" colspan="1">58 (56)</td><td align="center" rowspan="4" valign="top" colspan="1">46 (44)</td><td align="center" rowspan="4" valign="top" colspan="1">16 (16)</td><td align="center" rowspan="4" valign="top" colspan="1">82 (84)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Black 14 (13)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Asian 0</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Other 2 (2)</td></tr><tr><td align="center" rowspan="4" valign="top" colspan="1">RVd</td><td align="center" rowspan="4" valign="top" colspan="1">103</td><td align="center" rowspan="4" valign="top" colspan="1">61 (54&#x02013;66)</td><td align="center" valign="top" rowspan="1" colspan="1">White 76 (74)</td><td align="center" rowspan="4" valign="top" colspan="1">60 (58)</td><td align="center" rowspan="4" valign="top" colspan="1">43 (42)</td><td align="center" rowspan="4" valign="top" colspan="1">14 (14)</td><td align="center" rowspan="4" valign="top" colspan="1">83 (86)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Black 14 (13)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Asian 0</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">other 2 (2)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Gay, 2023 (IsKia Trial) [<xref rid="cnr270171-bib-0012" ref-type="bibr">12</xref>].</td><td align="center" rowspan="2" valign="top" colspan="1">3</td><td align="center" rowspan="2" valign="top" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">IsaKRd</td><td align="center" valign="top" rowspan="1" colspan="1">151</td><td align="center" valign="top" rowspan="1" colspan="1">61 (55&#x02013;66)</td><td align="center" rowspan="2" valign="top" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">72 (48)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">115 (82)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">KRd</td><td align="center" valign="top" rowspan="1" colspan="1">151</td><td align="center" valign="top" rowspan="1" colspan="1">60 (54&#x02013;63)</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">67 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">113 (81)</td></tr><tr><td align="left" rowspan="8" valign="top" colspan="1">Sonneveld, 2024 (PERSEUS) [<xref rid="cnr270171-bib-0010" ref-type="bibr">10</xref>].</td><td align="center" rowspan="8" valign="top" colspan="1">3</td><td align="center" rowspan="8" valign="top" colspan="1">47.5</td><td align="center" rowspan="4" valign="top" colspan="1">D&#x02010;VRd</td><td align="center" rowspan="4" valign="top" colspan="1">355</td><td align="center" rowspan="4" valign="top" colspan="1">61 (32&#x02013;70)</td><td align="center" valign="top" rowspan="1" colspan="1">White 330 (93)</td><td align="center" rowspan="4" valign="top" colspan="1">211 (59.4)</td><td align="center" rowspan="4" valign="top" colspan="1">NA</td><td align="center" rowspan="4" valign="top" colspan="1">76 (21.4)</td><td align="center" rowspan="4" valign="top" colspan="1">264 (74.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Black 5 (1.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Asian 4 (1.1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Other 4 (1.1)</td></tr><tr><td align="center" rowspan="4" valign="top" colspan="1">VRd</td><td align="center" rowspan="4" valign="top" colspan="1">354</td><td align="center" rowspan="4" valign="top" colspan="1">59 (31&#x02013;70)</td><td align="center" valign="top" rowspan="1" colspan="1">White 323 (91.2)</td><td align="center" rowspan="4" valign="top" colspan="1">205 (57.9)</td><td align="center" rowspan="4" valign="top" colspan="1">NA</td><td align="center" rowspan="4" valign="top" colspan="1">78 (22)</td><td align="center" rowspan="4" valign="top" colspan="1">266 (75.1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Black 4 (1.1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Asian 6 (1.7)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Other 3 (0.8)</td></tr></tbody></table><table-wrap-foot id="cnr270171-ntgp-0002"><fn id="cnr270171-note-0002"><p>Abbreviations: D, daratumumab; d, dexamethasone; Isa, isatuximab; K, carfilzomib; R, lenalidomide; T, thalidomide; V, bortezomib.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cnr270171-sec-0016"><label>3.2</label><title>Efficacy Outcomes</title><sec id="cnr270171-sec-0017"><label>3.2.1</label><title>Progression&#x02010;Free Survival</title><p>A total of three trials reported PFS [<xref rid="cnr270171-bib-0008" ref-type="bibr">8</xref>, <xref rid="cnr270171-bib-0010" ref-type="bibr">10</xref>, <xref rid="cnr270171-bib-0020" ref-type="bibr">20</xref>]. Quadruplet therapy was associated with a statistically significant improvement in PFS (HR 0.44; 95% CI 0.35&#x02013;0.56; <italic toggle="yes">I</italic>
<sup>2</sup>: 0%) when compared to triplet therapy. The results of PFS analyses are shown in Figure&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S3</xref> in the supplement.</p><p>On subgroup analysis by cytogenetic risk, quadruplet therapy was associated with a statistically significant improvement in PFS for both HiR (HR 0.62; 95% CI 0.41&#x02013;0.92) and SR group (HR 0.38; 95% CI 0.27&#x02013;0.52). There was a statistically significant difference in treatment effect by cytogenetic risk (<italic toggle="yes">P</italic>
<sub>int</sub>: 0.0). Additional details can be found in Figure&#x000a0;<xref rid="cnr270171-supitem-0001" ref-type="supplementary-material">S1</xref>&#x000a0;in the supplement.</p></sec><sec id="cnr270171-sec-0018"><label>3.2.2</label><title>Overall Survival</title><p>A total of two trials reported OS [<xref rid="cnr270171-bib-0008" ref-type="bibr">8</xref>, <xref rid="cnr270171-bib-0020" ref-type="bibr">20</xref>]. No statistically significant difference in OS was observed between quadruplet therapy and triplet therapy (HR 0.55; 95% CI 0.28&#x02013;1.08; <italic toggle="yes">I</italic>
<sup>2</sup>: 28%). OS results are available in Figure&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S4</xref> in the supplement.</p></sec><sec id="cnr270171-sec-0019"><label>3.2.3</label><title>Response Rates</title><p>Quadruplet therapy was associated with a statistically significant improvement in ORR (OR 1.77; 95% CI 1.02&#x02013;3.06; <italic toggle="yes">I</italic>
<sup>2</sup>: 35%), sCR (OR 1.72; 95% CI 1.07&#x02013;2.77; <italic toggle="yes">I</italic>
<sup>2</sup>: 84%), CR or better (OR 2.04; 95% CI 1.28&#x02013;3.25; <italic toggle="yes">I</italic>
<sup>2</sup>: 79%) and VGPR or better (OR 1.97; 95% CI 1.31&#x02013;2.96; <italic toggle="yes">I</italic>
<sup>2</sup>: 66%). Quadruplet therapy was associated with a statistically significant improvement in MRD negativity rate (OR 2.67; 95% CI 1.79&#x02013;3.99; <italic toggle="yes">I</italic>
<sup>2</sup>: 83%). The detailed results of response rates are presented in Figures&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S5&#x02013;S9</xref> in the supplement. Quadruplet therapy was associated with a statistically significant improvement in MRD negativity rate for both HiR (OR 2.01; 95% CI 1.41&#x02013;2.86) and SR group (OR 2.60; 95% CI 1.84&#x02013;3.69). There was no statistically significant difference in treatment effect by cytogenetic risk group (<italic toggle="yes">P</italic>
<sub>int</sub>: 0.31). Quadruplet therapy was associated with a statistically significant improvement in MRD negativity rate in the double&#x02010;hit (OR 4.21; 95% CI 1.06&#x02013;16.70) and single&#x02010;hit HiR group (OR 1.86; 95% CI 0.95&#x02013;3.64). There was no statistically significant difference in treatment effect between the two groups (<italic toggle="yes">P</italic>
<sub>int</sub>: 0.29). Additional subgroup analyzes have been presented for MRD negativity rate in Figures&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S17&#x02013;S24</xref> in the supplement.</p></sec></sec><sec id="cnr270171-sec-0020"><label>3.3</label><title>Safety Outcomes</title><p>No statistically significant difference was observed for G&#x02009;&#x02265;&#x02009;3 AEs between quadruplet and triplet therapy (OR 1.21; 95% CI 0.92&#x02013;1.58; <italic toggle="yes">I</italic>
<sup>2</sup>: 49%). However, quadruplet therapy was associated with a statistically significant increase in the risk of all&#x02010;grade thrombocytopenia (OR 1.64; 95% CI 1.37&#x02013;1.97; <italic toggle="yes">I</italic>
<sup>2</sup>: 0%), neutropenia (OR 2.24; 95% CI 1.67&#x02013;3.02; <italic toggle="yes">I</italic>
<sup>2</sup>: 62%) and infections (OR 1.88; 95% CI 1.07&#x02013;3.31; <italic toggle="yes">I</italic>
<sup>2</sup>: 82%). There was no statistically significant difference between quadruplet and triplet therapy with regard to all&#x02010;grade lymphopenia (OR 1.09; 95% CI 0.62&#x02013;1.89; <italic toggle="yes">I</italic>
<sup>2</sup>: 79%), and anemia (OR 1.06; 95% CI 0.83&#x02013;1.37; <italic toggle="yes">I</italic>
<sup>2</sup>: 0%). Safety analyses are presented in Figures&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S10&#x02013;S15</xref> in the supplement.</p></sec><sec id="cnr270171-sec-0021"><label>3.4</label><title>Risk of Bias</title><p>The overall risk of bias was judged as &#x0201c;low&#x0201d; or &#x0201c;some concerns&#x0201d;. For the GRIFFIN trial [<xref rid="cnr270171-bib-0009" ref-type="bibr">9</xref>], some concerns were noted due to reported protocol deviations. For the Iskia trial [<xref rid="cnr270171-bib-0012" ref-type="bibr">12</xref>], some concerns were noted in three domains as the risk of bias could not be ascertained from the limited data in the published abstract. The domain&#x02010;wise assessment is presented in Figure&#x000a0;<xref rid="cnr270171-supitem-0002" ref-type="supplementary-material">S2</xref> in the supplement.</p></sec><sec id="cnr270171-sec-0022"><label>3.5</label><title>Certainty of Evidence</title><p>The certainty of evidence ranged from high to moderate, except for OS, which was rated low primarily due to serious imprecision and inconsistency, and for G&#x02009;&#x02265;&#x02009;AEs, which was rated low due to serious imprecision. A detailed assessment is presented in Table&#x000a0;<xref rid="cnr270171-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="cnr270171-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Certainty of evidence according to the GRADE approach.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="5" valign="bottom" rowspan="1">Certainty assessment</th><th align="center" colspan="2" valign="bottom" rowspan="1">No of patients</th><th align="center" colspan="2" valign="bottom" rowspan="1">Effect</th><th align="center" rowspan="2" valign="bottom" colspan="1">Certainty</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">&#x02116; of studies</th><th align="center" valign="bottom" rowspan="1" colspan="1">Risk of bias</th><th align="center" valign="bottom" rowspan="1" colspan="1">Inconsistency</th><th align="center" valign="bottom" rowspan="1" colspan="1">Indirectness</th><th align="center" valign="bottom" rowspan="1" colspan="1">Imprecision</th><th align="center" valign="bottom" rowspan="1" colspan="1">Quadruplet therapy</th><th align="center" valign="bottom" rowspan="1" colspan="1">Triplet therapy</th><th align="center" valign="bottom" rowspan="1" colspan="1">Relative (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Absolute (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="10" valign="top" rowspan="1">Progression free survival</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">1002</td><td align="center" valign="top" rowspan="1" colspan="1">999</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>HR 0.63</bold> (0.42 to 0.96)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>294 more per 1000</bold> (from 209 more to 368 more)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x02a01;&#x02a01; High</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Overall survival</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="cnr270171-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">647</td><td align="center" valign="top" rowspan="1" colspan="1">645</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>HR 0.55</bold> (0.28 to 1.008)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>35 fewer per 1000</bold> (from 57 fewer to 6 more)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x025ef;&#x025ef; Low</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Overall response rate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="cnr270171-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">945/998 (94.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">909/994 (91.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>OR 1.49</bold> (1.05 to 2.10)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>26 more per 1000</bold> (from 4 more to 43 more)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x02a01;&#x025ef; Moderate</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">MRD negativity rate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="cnr270171-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">914/1484 (61.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">578/1479 (39.19%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>OR 2.67</bold> (1.79 to 3.99)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>241 more per 1000</bold> (from 144 more to 328 more)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x02a01;&#x025ef; Moderate</td></tr><tr><td align="left" colspan="10" valign="top" rowspan="1">Grade 3 or higher adverse events</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Not serious</td><td align="center" valign="top" rowspan="1" colspan="1">Serious<xref rid="cnr270171-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">865/1316 (65.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">832/1315 (63.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>OR 1.21</bold> (0.92 to 1.58)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>43 more per 1000</bold> (from 20 fewer to 99 more)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x025ef;&#x025ef; Low</td></tr></tbody></table><table-wrap-foot id="cnr270171-ntgp-0003"><fn id="cnr270171-note-0003"><p>Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio.</p></fn><fn id="cnr270171-note-0004"><label>
<sup>a</sup>
</label><p>Statistically significant heterogeneity with non&#x02010;overlapping confidence intervals.</p></fn><fn id="cnr270171-note-0005"><label>
<sup>b</sup>
</label><p>Serious imprecision due to wide confidence intervals.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="cnr270171-sec-0023"><label>4</label><title>Discussion</title><p>Frontline treatment for MM has progressed from doublet regimens to triplets, and now the incorporation of quadruplets represents the latest advancement. Our study uniquely synthesizes evidence from five trials assessing anti&#x02010;CD38 mAbs (Dara or Isa) in a comprehensive cohort of 2963 patients, addressing critical clinical questions regarding optimal therapy in TENDMM. The findings suggest that the addition of anti&#x02010;CD38 mAbs is associated with superior PFS compared to the standard&#x02010;of&#x02010;care triplet regimen.</p><p>The available evidence indicates that the cytogenetic risk group may be a key factor in frontline treatment. Quadruplet therapy demonstrated efficacy in prolonging PFS across both standard&#x02010;risk and high&#x02010;risk cytogenetic groups. Our results did not show an overall OS advantage. Notably, OS data remain immature for many of the included trials [<xref rid="cnr270171-bib-0010" ref-type="bibr">10</xref>, <xref rid="cnr270171-bib-0011" ref-type="bibr">11</xref>, <xref rid="cnr270171-bib-0012" ref-type="bibr">12</xref>] with longer&#x02010;term follow&#x02010;up ongoing. In terms of response rates, our analysis revealed significantly improved rates of ORR, sCR, CR or better, and VGPR or better. Furthermore, the odds of achieving MRD&#x02010;negative status were significantly higher with quadruplet therapy, and this benefit was consistent regardless of cytogenetic risk. The toxicity profile of quadruplet therapy was acceptable, with no significant difference in the risk of grade &#x02265;&#x02009;3 adverse events (AEs) compared to the triplet regimens. However, we noted an increased risk of all&#x02010;grade infections, neutropenia, and thrombocytopenia. Given the generally healthier status of transplant&#x02010;eligible patients, this toxicity profile appears manageable.</p><p>Despite advances in novel therapies, outcomes for the HiR population remain suboptimal due to an increased risk of early recurrence [<xref rid="cnr270171-bib-0022" ref-type="bibr">22</xref>]. Clinical trials specifically targeting responses in HiR MM are lacking, and large phase 3 studies have traditionally enrolled a small subset of HiR patients, affecting statistical significance. Furthermore, prognosis for HiR patients differs based on the number of cytogenetic abnormalities [<xref rid="cnr270171-bib-0021" ref-type="bibr">21</xref>]. Hence, there is a need for reliable surrogate endpoints to accelerate the adoption of newer approaches for this vulnerable subgroup. MRD negativity rate is one such endpoint that has established its prognostic value in the setting of MM. A meta&#x02010;analysis by Landgren et&#x000a0;al. [<xref rid="cnr270171-bib-0023" ref-type="bibr">23</xref>], which combined eight studies with 4907 newly diagnosed patients, demonstrated a significant relationship between MRD negativity and PFS (OR 4.02; 95% CI 2.57&#x02013;5.46). Given the limited PFS data in our analysis, the pooled effect of MRD negativity warrants careful consideration. Our subgroup analysis revealed significant benefits for MRD negativity in both double&#x02010;hit and single&#x02010;hit patients; however, these findings should be interpreted with caution due to the small sample size as only two of the five included trials reported data for this important subgroup. Further subgroup analysis based on MRD negativity showed consistent benefit for quadruplet therapy across gender, ISS stages, type of MM, as well as ECOG performance status, with no subgroup differences observed. In a real&#x02010;world study by Joseph et&#x000a0;al. [<xref rid="cnr270171-bib-0024" ref-type="bibr">24</xref>]. Dara&#x02010;based quadruplet therapy in comparison with triplet therapy (D&#x02010;RVd vs. RVd) revealed an improved 2&#x02010;year PFS in both HiR (83% vs. 69%) and SR groups (94% vs. 84%). Even though the follow&#x02010;up period was shorter for the D&#x02010;RVd cohort (19.1 vs. 90&#x02009;months), the results demonstrated an early benefit, supporting our findings that an upfront intensive treatment approach with an anti&#x02010;CD38 mAb&#x02010;based quadruplet regimen may achieve prolonged remission in both HiR and SR groups. Based on the existing evidence of an improved MRD and PFS, we suggest that the incorporation of anti&#x02010;CD38 mAb&#x02010;based quadruplets may provide the best outcome in the HiR subgroup.</p><p>Current National Comprehensive Cancer Network (NCCN) guidelines recommend Dara&#x02010;based quadruplet as the preferred regimen in TENDMM, with an Isa&#x02010;based regimen also categorized as a recommended option [<xref rid="cnr270171-bib-0025" ref-type="bibr">25</xref>].</p></sec><sec id="cnr270171-sec-0024"><label>5</label><title>Strengths and Limitations</title><p>This meta&#x02010;analysis offers significant insights to inform clinical practice, underpinned by rigorous methodology and quality assessment, integrating the most current evidence from recent trials. However, our analysis is limited by a small number of trials and the use of only study&#x02010;level data. There was a limited follow&#x02010;up, with variable follow&#x02010;up durations between the trials. The included trials constituted varied backbone regimens, which differed with regard to the duration of induction and consolidation therapy. Additionally, maintenance regimens also varied between the trials, which may have confounded the ability to determine the independent contribution of the regimen during each phase of the treatment.</p><p>Only two trials reported OS, with future studies required to validate long&#x02010;term follow&#x02010;up results. There was no homogeneous definition of HiR MM across the trials (Table&#x000a0;<xref rid="cnr270171-supitem-0001" ref-type="supplementary-material">S3</xref> in supplement). Additionally, there was inconsistent reporting of outcomes across the different trials and limited data for the cytogenetic subgroups (Table&#x000a0;<xref rid="cnr270171-supitem-0001" ref-type="supplementary-material">S1</xref> in supplement). Due to the ongoing nature of the trials, data was insufficient to pool outcomes following maintenance therapy. Finally, the small number of included studies precluded formal assessment of publication bias.</p></sec><sec sec-type="conclusions" id="cnr270171-sec-0025"><label>6</label><title>Conclusions</title><p>The results support quadruplet therapy with anti&#x02010;CD38 mAbs as the new standard of care for TENDMM. This approach appears particularly promising for HiR patients, offering improved MRD and PFS outcomes. Anti&#x02010;CD38 mAb&#x02010;based regimens are effective and well tolerated in TENDMM. However, continued efforts are required to optimize disease control in HiR subgroups, particularly among double&#x02010;hit patients.</p></sec><sec id="cnr270171-sec-0026"><title>Author Contributions</title><p>
<bold>Aneeta Channar:</bold> data curation, methodology and manuscript writing. <bold>Aneeta Channar, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Muhammad Husnain:</bold> methodology, statistical analysis, and manuscript review/editing. <bold>Aneeta Channar, Arifa Bibi, Akshat Saxena, Nikita Tripathi:</bold> conceptualization, initial screening, and data curation. <bold>Muhammad Ali Khan</bold>, <bold>Arifa Bibi, Ammad Raina, Kaneez Zahra Rubab Khakwani:</bold> initial screening and data curation. <bold>Muhammad Husnain:</bold> conceptualization and manuscript review/editing. <bold>Ahmad Iftikhar, Irbaz Bin Riaz:</bold> manuscript review/editing. <bold>Irbaz Bin Riaz, Ahmad Iftikhar, Muhammad Husnain:</bold> conceptualization, data curation, methodology, supervision, and manuscript review/editing. All authors reviewed and edited the final version of the manuscript.</p></sec><sec sec-type="COI-statement" id="cnr270171-sec-0027"><title>Disclosure</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="cnr270171-sec-0028"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cnr270171-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Data S1.</bold> Supporting Information.</p></caption><media xlink:href="CNR2-8-e70171-s002.pdf"/></supplementary-material><supplementary-material id="cnr270171-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Data S2.</bold> Supporting Information.</p></caption><media xlink:href="CNR2-8-e70171-s001.docx"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="cnr270171-sec-0030"><title>Data Availability Statement</title><p>The datasets extracted and analyzed during the current study are available from the corresponding author upon request.</p></sec><ref-list content-type="cited-references" id="cnr270171-bibl-0001"><title>References</title><ref id="cnr270171-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cnr270171-cit-0001">
<string-name>
<given-names>S. V.</given-names>
<surname>Rajkumar</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Dimopoulos</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Palumbo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>15</volume>, no. <issue>12</issue> (<year>2014</year>): <fpage>e538</fpage>&#x02013;<lpage>e548</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70442-5</pub-id>.<pub-id pub-id-type="pmid">25439696</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cnr270171-cit-0002">
<string-name>
<given-names>R. L.</given-names>
<surname>Siegel</surname>
</string-name>, <string-name>
<given-names>K. D.</given-names>
<surname>Miller</surname>
</string-name>, <string-name>
<given-names>H. E.</given-names>
<surname>Fuchs</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Jemal</surname>
</string-name>, &#x0201c;<article-title>Cancer Statistics, 2021</article-title>,&#x0201d; <source>CA: A Cancer Journal for Clinicians</source>
<volume>71</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>7</fpage>&#x02013;<lpage>33</lpage>, <pub-id pub-id-type="doi">10.3322/caac.21654</pub-id>.<pub-id pub-id-type="pmid">33433946</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cnr270171-cit-0003">
<string-name>
<given-names>D.</given-names>
<surname>Kazandjian</surname>
</string-name>, &#x0201c;<article-title>Multiple Myeloma Epidemiology and Survival: A Unique Malignancy</article-title>,&#x0201d; <source>Seminars in Oncology</source>
<volume>43</volume>, no. <issue>6</issue> (<year>2016</year>): <fpage>676</fpage>&#x02013;<lpage>681</lpage>, <pub-id pub-id-type="doi">10.1053/j.seminoncol.2016.11.004</pub-id>.<pub-id pub-id-type="pmid">28061985</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cnr270171-cit-0004">
<string-name>
<given-names>S. K.</given-names>
<surname>Kumar</surname>
</string-name>, <string-name>
<given-names>J. H.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Lahuerta</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy With IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study</article-title>,&#x0201d; <source>Leukemia</source>
<volume>26</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>149</fpage>&#x02013;<lpage>157</lpage>, <pub-id pub-id-type="doi">10.1038/leu.2011.196</pub-id>.<pub-id pub-id-type="pmid">21799510</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cnr270171-cit-0005">
<string-name>
<given-names>S. V.</given-names>
<surname>Rajkumar</surname>
</string-name>, &#x0201c;<article-title>Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management</article-title>,&#x0201d; <source>American Journal of Hematology</source>
<volume>97</volume>, no. <issue>8</issue> (<year>2022</year>): <fpage>1086</fpage>&#x02013;<lpage>1107</lpage>, <pub-id pub-id-type="doi">10.1002/ajh.26590</pub-id>.<pub-id pub-id-type="pmid">35560063</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cnr270171-cit-0006">
<string-name>
<given-names>S.</given-names>
<surname>Kumar</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Flinn</surname>
</string-name>, <string-name>
<given-names>P. G.</given-names>
<surname>Richardson</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Randomized, Multicenter, Phase 2 Study (EVOLUTION) of Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Previously Untreated Multiple Myeloma</article-title>,&#x0201d; <source>Blood</source>
<volume>119</volume>, no. <issue>19</issue> (<year>2012</year>): <fpage>4375</fpage>&#x02013;<lpage>4382</lpage>, <pub-id pub-id-type="doi">10.1182/blood-2011-11-395749</pub-id>.<pub-id pub-id-type="pmid">22422823</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cnr270171-cit-0007">
<string-name>
<given-names>K.</given-names>
<surname>Wudhikarn</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Wills</surname>
</string-name>, and <string-name>
<given-names>A. M.</given-names>
<surname>Lesokhin</surname>
</string-name>, &#x0201c;<article-title>Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action</article-title>,&#x0201d; <source>Best Practice &#x00026; Research Clinical Haematology</source>
<volume>33</volume>, no. <issue>1</issue> (<year>2020</year>): <elocation-id>101143</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.beha.2020.101143</pub-id>.<pub-id pub-id-type="pmid">32139009</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cnr270171-cit-0008">
<string-name>
<given-names>P.</given-names>
<surname>Moreau</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Attal</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Hulin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem&#x02010;Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open&#x02010;Label, Phase 3 Study</article-title>,&#x0201d; <source>Lancet</source>
<volume>394</volume>, no. <issue>10192</issue> (<year>2019</year>): <fpage>29</fpage>&#x02013;<lpage>38</lpage>, <pub-id pub-id-type="doi">10.1016/s0140-6736(19)31240-1</pub-id>.<pub-id pub-id-type="pmid">31171419</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cnr270171-cit-0009">
<string-name>
<given-names>P. M.</given-names>
<surname>Voorhees</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Kaufman</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Laubach</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant&#x02010;Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial</article-title>,&#x0201d; <source>Blood</source>
<volume>136</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>936</fpage>&#x02013;<lpage>945</lpage>, <pub-id pub-id-type="doi">10.1182/blood.2020005288</pub-id>.<pub-id pub-id-type="pmid">32325490</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cnr270171-cit-0010">
<string-name>
<given-names>P.</given-names>
<surname>Sonneveld</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Dimopoulos</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Boccadoro</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>390</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>301</fpage>&#x02013;<lpage>313</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2312054</pub-id>.<pub-id pub-id-type="pmid">38084760</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cnr270171-cit-0011">
<string-name>
<given-names>H.</given-names>
<surname>Goldschmidt</surname>
</string-name>, <string-name>
<given-names>E. K.</given-names>
<surname>Mai</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Bertsch</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed, Transplantation&#x02010;Eligible Patients With Multiple Myeloma (GMMG&#x02010;HD7): Part 1 of an Open&#x02010;Label, Multicentre, Randomised, Active&#x02010;Controlled, Phase 3 Trial</article-title>,&#x0201d; <source>Lancet Haematology</source>
<volume>9</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>e810</fpage>&#x02013;<lpage>e821</lpage>, <pub-id pub-id-type="doi">10.1016/s2352-3026(22)00263-0</pub-id>.<pub-id pub-id-type="pmid">36328040</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cnr270171-cit-0012">
<string-name>
<given-names>F.</given-names>
<surname>Gay</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Roeloffzen</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Dimopoulos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Results of the Phase III Randomized Iskia Trial: Isatuximab&#x02010;Carfilzomib&#x02010;Lenalidomide&#x02010;Dexamethasone vs Carfilzomib&#x02010;Lenalidomide&#x02010;Dexamethasone as Pre&#x02010;Transplant Induction and Post&#x02010;Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients</article-title>,&#x0201d; <source>Blood</source>
<volume>142</volume>, no. <issue>Suppl 1</issue> (<year>2023</year>): <fpage>4</fpage>, <pub-id pub-id-type="doi">10.1182/blood-2023-177546</pub-id>.<pub-id pub-id-type="pmid">37410508</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cnr270171-cit-0013">
<string-name>
<given-names>N. C.</given-names>
<surname>Munshi</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Avet&#x02010;Loiseau</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Rawstron</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta&#x02010;Analysis</article-title>,&#x0201d; <source>JAMA Oncology</source>
<volume>3</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>28</fpage>&#x02013;<lpage>35</lpage>, <pub-id pub-id-type="doi">10.1001/jamaoncol.2016.3160</pub-id>.<pub-id pub-id-type="pmid">27632282</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cnr270171-cit-0014">
<string-name>
<given-names>L. L.</given-names>
<surname>Chong</surname>
</string-name>, <string-name>
<given-names>Y. Y.</given-names>
<surname>Soon</surname>
</string-name>, <string-name>
<given-names>C. Y.</given-names>
<surname>Soekojo</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ooi</surname>
</string-name>, <string-name>
<given-names>W. J.</given-names>
<surname>Chng</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>de Mel</surname>
</string-name>, &#x0201c;<article-title>Daratumumab&#x02010;Based Induction Therapy for Multiple Myeloma: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Critical Reviews in Oncology/Hematology</source>
<volume>159</volume> (<year>2021</year>): <elocation-id>103211</elocation-id>.<pub-id pub-id-type="pmid">33387628</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cnr270171-cit-0015">
<string-name>
<given-names>S.</given-names>
<surname>Giri</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Grimshaw</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bal</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High&#x02010;Risk Cytogenetic Factors: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>JAMA Oncology</source>
<volume>6</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>1759</fpage>&#x02013;<lpage>1765</lpage>.<pub-id pub-id-type="pmid">32970151</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cnr270171-cit-0016">
<string-name>
<given-names>S.</given-names>
<surname>Kiss</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Gede</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Hegyi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Addition of Daratumumab to Multiple Myeloma Backbone Regimens Significantly Improves Clinical Outcomes: A Systematic Review and Meta&#x02010;Analysis of Randomised Controlled Trials</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>21916</fpage>.<pub-id pub-id-type="pmid">34754015</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cnr270171-cit-0017">
<string-name>
<given-names>W.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Sun</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Daratumumab Added to Standard of Care in Patients With Newly Diagnosed Multiple Myeloma: A Network Meta&#x02010;Analysis</article-title>,&#x0201d; <source>European Journal of Haematology</source>
<volume>103</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>542</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">31444819</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cnr270171-cit-0018">
<string-name>
<given-names>M. J.</given-names>
<surname>Page</surname>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>McKenzie</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Bossuyt</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title>,&#x0201d; <source>BMJ</source>
<volume>372</volume> (<year>2021</year>): <elocation-id>n71</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>.<pub-id pub-id-type="pmid">33782057</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cnr270171-cit-0019">
<string-name>
<given-names>J. A. C.</given-names>
<surname>Sterne</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Savovi&#x00107;</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Page</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials</article-title>,&#x0201d; <source>BMJ</source>
<volume>366</volume> (<year>2019</year>): <elocation-id>l4898</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id>.<pub-id pub-id-type="pmid">31462531</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cnr270171-cit-0020">
<string-name>
<given-names>P. M.</given-names>
<surname>Voorhees</surname>
</string-name>, <string-name>
<given-names>D. W.</given-names>
<surname>Sborov</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Laubach</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Addition of Daratumumab to Lenalidomide, Bortezomib, and Dexamethasone for Transplantation&#x02010;Eligible Patients With Newly Diagnosed Multiple Myeloma (GRIFFIN): Final Analysis of an Open&#x02010;Label, Randomised, Phase 2 Trial</article-title>,&#x0201d; <source>Lancet Haematology</source>
<volume>10</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>e825</fpage>&#x02013;<lpage>e837</lpage>, <pub-id pub-id-type="doi">10.1016/s2352-3026(23)00217-x</pub-id>.<pub-id pub-id-type="pmid">37708911</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cnr270171-cit-0021">
<string-name>
<given-names>A.</given-names>
<surname>Chari</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Kaufman</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Laubach</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Daratumumab in Transplant&#x02010;Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Clinically Relevant Subgroups in GRIFFIN</article-title>,&#x0201d; <source>Blood Cancer Journal</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>107</fpage>.<pub-id pub-id-type="pmid">38977707</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0022"><label>22</label><mixed-citation publication-type="book" id="cnr270171-cit-0022">
<string-name>
<given-names>J.</given-names>
<surname>Caro</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Hadidi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Usmani</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Yee</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Raje</surname>
</string-name>, and <string-name>
<given-names>F. E.</given-names>
<surname>Davies</surname>
</string-name>, <source>How to Treat High&#x02010;Risk Myeloma at Diagnosis and Relapse</source> (<publisher-name>American Society of Clinical Oncology Educational Book</publisher-name>, <year>2021</year>), <fpage>291</fpage>&#x02013;<lpage>309</lpage>.</mixed-citation></ref><ref id="cnr270171-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cnr270171-cit-0023">
<string-name>
<given-names>O.</given-names>
<surname>Landgren</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Prior</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Masterson</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>EVIDENCE Meta&#x02010;Analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma</article-title>,&#x0201d; <source>Blood</source>
<volume>144</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>359</fpage>&#x02013;<lpage>367</lpage>, <pub-id pub-id-type="doi">10.1182/blood.2024024371</pub-id>.<pub-id pub-id-type="pmid">38768337</pub-id>
</mixed-citation></ref><ref id="cnr270171-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cnr270171-cit-0024">
<string-name>
<given-names>N. S.</given-names>
<surname>Joseph</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Kaufman</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dicamillo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Comparison of Response and Survival Outcomes in Standard&#x02010; and High&#x02010;Risk Newly Diagnosed Transplant&#x02010;Eligible Multiple Myeloma (NDMM) Patients Treated With Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D&#x02010;RVD)</article-title>,&#x0201d; <source>Blood</source>
<volume>142</volume> (<year>2023</year>): <fpage>647</fpage>, <pub-id pub-id-type="doi">10.1182/blood-2023-187339</pub-id>.</mixed-citation></ref><ref id="cnr270171-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="cnr270171-cit-0025">
<collab collab-type="authors">Network NCC</collab>
, <article-title>&#x0201c;Multiple Myeloma (Version 2.2024),&#x0201d;</article-title> accessed February 28, 2024, <ext-link xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf</ext-link>.</mixed-citation></ref></ref-list></back></article>